<DOC>
	<DOCNO>NCT03080935</DOCNO>
	<brief_summary>This multicenter , open-label extension ( OLE ) study design assess extend long-term safety evolocumab subject complete FOURIER trial ( Study 20110118 ) . Approximately 1600 subject enrol study . This study continue 260 week ( approximately 5 year ) .</brief_summary>
	<brief_title>Fourier Open-label Extension Study Subjects With Clinically Evident Cardiovascular Disease Selected European Countries</brief_title>
	<detailed_description>This multicenter , open-label extension ( OLE ) study design assess extend long-term safety evolocumab subject complete FOURIER trial ( Study 20110118 ) . FOURIER randomize placebo-controlled study evolocumab , patient clinically evident atherosclerotic CVD stable effective statin therapy . Subjects sit participate FOURIER OLE ( Study 20160250 ) eligible sign FOURIER OLE inform consent enrol completion FOURIER . The FOURIER OLE study require laboratory assessment day 1 , week 12 , thereafter approximately every 6 month day 1 ; correspond blood sample process use central laboratory . Upon enrollment FOURIER OLE study , subject receive evolocumab 140 mg every 2 week ( Q2W ) 420 mg monthly ( QM ) accord preference . Frequency correspond dose administration change scheduled time point evolocumab supply subject , provided appropriate supply available . It recommend subject continue background lipid-lowering therapy ( LLT ) , include statin , take FOURIER . This study continue 260 week ( approximately 5 year ) . Subjects end administration evolocumab continue study assessment end study . All subject follow complete procedures/assessments enrollment date study termination unless subject withdrawn consent , irrespective whether subject continue receive treatment .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Subject provide informed consent prior initiation studyspecific activities/procedures . Subject complete FOURIER ( Study 20110118 ) still receive assign Investigational Product . Permanent discontinuation Investigational Product FOURIER reason include adverse event serious adverse event . Currently receive treatment another investigational device drug study , less 4 week since end treatment another investigational device drug study ( y ) . Other investigational procedure participate study exclude . Subject likely available complete protocolrequired study visit procedure , and/or comply require study procedure best subject investigator 's knowledge . History evidence clinically significant disorder , condition disease , opinion investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedures completion . Subject known sensitivity active substance excipients ( eg , carboxymethylcellulose ) administer dose . Females pregnant breastfeeding planning become pregnant breastfeed treatment evolocumab additional 15 week treatment evolocumab discontinues . Female subject childbearing potential unwilling use acceptable method effective contraception treatment additional 15 week last dose protocolrequired therapy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>